Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2015-04-22 Major Shareholding Noti…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Top 20 Holders 1 page 47.0KB
Major Shareholding Notification Classification · 95% confidence The document lists the top 20 holders of ordinary fully paid shares of Admedus Limited, including the number of units held and percentage ownership. This is a notification of significant share ownership levels and their distribution among shareholders. There is no indication of a report, financial statements, or management commentary. The content fits the definition of a Major Shareholding Notification, which reports changes or details in significant share ownership levels.
2015-04-22 English
Admedus appoints Genpharm as CardioCel distributor in MENA 3 pages 321.2KB
Capital/Financing Update Classification · 90% confidence The document is an ASX release announcing the appointment of Genpharm as a distributor for CardioCel in the Middle East and North Africa. It focuses on a business partnership and distribution agreement, with no financial statements, regulatory filings, or detailed financial data. It is a corporate announcement about a commercial agreement rather than a financial report, management change, or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company business development and expansion of product distribution.
2015-04-21 English
Appendix 3B - Rights Issue 14 pages 807.4KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B filing submitted to the Australian Stock Exchange (ASX), which is a standard form used for announcing new issues of securities, specifically a Rights Issue in this case. It details the allotment of new fully paid ordinary shares, the issue price, the purpose of the issue, and other related information about the capital raising event. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital raising event and new share issuance. This fits the definition of a Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the share issue, confirming it is not merely a brief announcement or a report publication notice.
2015-04-21 English
Appendix 3Y - Change of Directors' Interest Notice 6 pages 353.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including shares acquired, disposed, and the nature of interests. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is over 10,000 characters and contains multiple notices for different directors, confirming it is a substantive filing rather than a brief announcement or certification. Therefore, the correct classification is DIRS (Director's Dealing).
2015-04-21 English
Admedus completes fully subscribed Rights Issue 2 pages 280.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release announcing the completion of a fully subscribed $16.1 million rights issue, along with a previous placement raising a total of approximately $28 million. It details the capital raising activities, allotment dates, and use of proceeds. There are no financial statements or detailed financial performance data included, nor is it a report or presentation. The content focuses on fundraising and capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely an announcement of a report publication, so it is not RPA or RNS. Confidence is high due to clear keywords like 'Rights Issue', 'Placement', 'capital raised', and 'Lead Manager'.
2015-04-16 English
Admedus Herpes Phase II - First dosing to commence 3 pages 285.8KB
Capital/Financing Update Classification · 90% confidence The document is an ASX release providing an update on the progress of a Phase II clinical trial for a herpes vaccine by Admedus Limited. It includes details about the study timeline, enrollment status, and expected interim results. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The content is a corporate announcement about ongoing clinical trial progress and expected milestones, typical of a Capital/Financing Update or a general corporate update. Given the focus on study progress and interim results timing, and no mention of fundraising or capital structure changes, the best fit is Capital/Financing Update (CAP) as it relates to development progress impacting company valuation and financing considerations. The document length (6468 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2015-04-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.